Osteogenics Secures North American Distribution of Resorba® Dental Sutures

July 01

LUBBOCK, Texas – Osteogenics Biomedical, a leader in the development of innovative dental bone grafting products, announces the acquisition of exclusive North American distribution rights for the premium German dental suture brand, Resorba®.

While most sutures in dentistry are simply repositioned from medicine, Resorba®, a major suture manufacturer in Germany since 1931, created a division exclusively for dentistry. Resorba® combines unique materials with specialty dental needles to create products better suited for dental surgery.

Among their unique product offering is their best-selling dental suture, Glycolon™, an absorbable suture with a monofilament construction comprised of polyglycolic acid (PGA) and polycaprolactone (PCL). The monofilament structure provides excellent handling properties, does not wick bacteria, and allows for atraumatic passage through tissue. Glycolon™ maintains 50 percent of its tensile strength for 11 to 13 days.

Resorba® dental suture needles are manufactured from premium tempered 300-series stainless steel. Select configurations are also available with a black needle that provides increased contrast in the mouth for enhanced visualization.

“Following the success of our own Cytoplast™ PTFE suture line, expansion of our suture portfolio was a long-term goal,” said Osteogenics president, Shane Shuttlesworth. “Resorba’s® focus on unique, premium products designed for dentistry fits perfectly within our product portfolio philosophy.”

Click here for more information on the complete line of Resorba® dental sutures, or contact a customer service specialist at 888.796.1923.